ARTICLE | Product Development
Alzheimer’s data from Lilly and Biogen converge on small effect for amyloid targeting
Both corroborate the amyloid hypothesis while simultaneously suggesting it’s not the path to a large effect size
March 15, 2021 12:45 AM UTC
Emerging data from anti-amyloid therapies from Eli Lilly and Biogen continue to mirror each other. Whether the consistent findings will bolster both therapies’ cases with regulators, or whether ...